40
1
5
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T41003 | KG5 | Raf , FLT , PDGFR , c-Kit | |
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer and antiangiogenic activities. | |||
T72605 | C-RAF kinase-IN-1 | ||
C-RAF kinase-IN-1 is a potent inhibitor of C-RAF kinase with an IC 50 of 0.193 μM. C-RAF kinase-IN-1 is a quinoline derivative. C-RAF kinase-IN-1 has the potential for the research of cancer diseases . | |||
T1792 | Regorafenib | BAY 73-4506,Fluoro-Sorafenib | Raf , VEGFR , c-RET , PDGFR , c-Kit , Autophagy |
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active. Regorafenib has antitumor and anti-angiogenic activity. | |||
T1845 | B-Raf IN 1 | Raf | |
B-Raf IN 1 is a B-Raf (IC50: 24 nM) and c-Raf (IC50: 25 nM) inhibitor. | |||
T1851 | ZM 336372 | Zinc00581684 | Apoptosis , Raf |
ZM 336372 is a potent and selective c-Raf inhibitor. | |||
T3711 | RAF709 | Raf | |
RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively. | |||
T5634 | Belvarafenib | Raf | |
Belvarafenib is a potent and pan RAF inhibitor with antineoplastic activity. The IC50 values of Belvarafenib are 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. | |||
T6882 | LY3009120 | DP-4978 | Raf , Autophagy |
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1. | |||
T6296 | RAF265 | CHIR-265 | Apoptosis , Raf , VEGFR , Autophagy |
RAF265 (CHIR-265) (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. Phase 2. | |||
T6525 | GW 5074 | GW5074,Raf1 Kinase Inhibitor I | Apoptosis , Raf |
GW 5074 (Raf1 Kinase Inhibitor I)(IC50=9 nM) is an effective and specific c-Raf inhibitor. It has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms. | |||
T4167 | Raf inhibitor 1 dihydrochloride | B-Raf inhibitor 1 dihydrochloride | Raf |
Raf inhibitor 1 dihydrochloride (B-Raf inhibitor 1 dihydrochloride) is a potent and selective B-Raf inhibitor. | |||
T1903 | Dabrafenib | GSK2118436A,GSK2118436 | Raf |
Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma. | |||
T6318 | AZ 628 | Apoptosis , Raf | |
AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc. | |||
T2074 | Raf inhibitor 1 | B-Raf inhibitor 1 | Raf |
B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor. | |||
T2473 | PLX-4720 | PLX4720 | Raf |
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations). | |||
T6348 | NVP-BHG712 | Raf , Bcr-Abl , Src , Ephrin Receptor | |
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respecti... | |||
T2382 | Vemurafenib | RO5185426,RG7204,PLX4032 | Raf , MAPK , ACK , Src , Autophagy |
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive... | |||
T11898 | LXH254 | Raf | |
LXH254 is a potent C-Raf and B-Raf inhibitor. | |||
T0093L | Sorafenib | Bay 43-9006 | Apoptosis , Raf , VEGFR , FLT , Ferroptosis , PDGFR , c-Kit , Autophagy |
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. Sorafenib has antitumor activity... | |||
T8474 | Dabrafenib Mesylate | GSK 2118436B,GSK2118436 Mesylate | Raf |
Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively). | |||
T6320 | GDC-0879 | GDC 0879,AR-00341677,GDC0879 | Raf |
GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well. | |||
T2295 | SB-590885 | Raf | |
SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay). The selectivity of SB590885 for B-Raf is 11-fold greater over c-Raf, no acts to other human kinases. | |||
T0093 | Sorafenib tosylate | Bay 43-9006 | Apoptosis , Raf , VEGFR , FLT , Ferroptosis , PDGFR , c-Kit , Autophagy |
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf). | |||
T1876 | Kobe0065 | Apoptosis , Raf , Ras | |
Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM. | |||
T6277 | Doramapimod | BIRB 796 | Raf , p38 MAPK , Autophagy |
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70. | |||
T2293 | SGX-523 | Raf , p38 MAPK , c-Met/HGFR , Bcr-Abl | |
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf. | |||
T2617 | SNS-314 Mesylate | SNS-314 | Aurora Kinase |
SNS-314 Mesylate (SNS-314) is an effective and specific Aurora A/B/C inhibitor (IC50: 9/31/3 nM). It is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2. | |||
T1892 | Kobe2602 | Raf , Ras | |
Kobe 2602 is an inhibitor of Ras that exhibits anticancer chemotherapeutic activities. | |||
T2624 | OSI-930 | OSI 930 | Apoptosis , c-Fms , Raf , VEGFR , FLT , CSF-1R , Src , c-Kit |
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors. | |||
TQ0048 | BI-882370 | Raf | |
BI-882370 is a specific RAF kinase inhibitor. BI-882370 inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases (IC50s: 0.4, 0.8 and 0.6 nM). BI-882370 also inhibits SRC family kinases. | |||
T12685 | RAF mutant-IN-1 | Others | |
RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively). | |||
T1886 | TAK-632 | Raf , FGFR , PDGFR , Aurora Kinase | |
TAK-632 is a potent pan-Raf inhibitor. | |||
T79813 | Raf inhibitor 3 | Raf | |
Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1]. | |||
T64194 | Belvarafenib TFA | ||
Belvarafenib TFA (HM95573 TFA) is a potent and broadly available rapidly accelerating inhibitor of fibrosarcoma kinase (RAF) that acts on B-RAF (IC50: 56 nM), B-RAFv600E (IC50: 7 nM) and C-RAF (IC50: 5 nM). | |||
T5172 | AZ304 | c-Fms , Raf , p38 MAPK , Autophagy | |
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM). | |||
T3641 | NVP-BAW2881 | BAW2881 | Raf , VEGFR , Bcr-Abl |
NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. | |||
T79572 | MAPK-IN-2 | EGFR | |
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell lines. It demonstrates robust suppression of the MAPK pathway (E... | |||
T10157 | Regorafénib N-oxyde (M2) | Raf , VEGFR , c-RET , PDGFR , c-Kit , Drug Metabolite | |
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2/46, 1.5, 22, 7, and 2.5 nM). | |||
T35578 | Phosphatidylserines (sodium salt) | Phosphatidylserines (sodium salt),L-α-Phosphatidylserine | |
Phosphatidylserine is a naturally occurring phospholipid that comprises 2-10% of total phospholipids in mammals and is enriched in the central nervous system, particularly the retina. It is anionic and found mainly on th... | |||
T14928 | Agerafenib hydrochloride | RXDX-105 hydrochloride,CEP-32496 (hydrochloride) | c-RET , c-Kit |
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM). |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T35577 | Phosphatidylserines (bovine) | ||
Phosphatidylserine is a naturally occurring phospholipid that comprises 2-10% of total phospholipids in mammals and is enriched in the central nervous system, particularly the retina. It is anionic and found mainly on th... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-05095 | RAF1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus Insect Cells |
RAF1 gene is the cellular homolog of viral raf gene (v-raf). The encoded protein is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds direct... | |||
TMPY-04411 | YES1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus Insect Cells |
Proto-oncogene tyrosine-protein kinase Yes, also known as Proto-oncogene c-Yes, p61-Yes and YES1, is a cytoplasm protein that belongs to the protein kinase superfamily, Tyr protein kinase family and SRC subfamily. YES1 /... | |||
TMPK-01456 | HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr... | |||
TMPK-01450 | HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr... | |||
TMPK-01451 | HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr... |